On Monday, Atyr Pharma Inc (NASDAQ: ATYR) opened higher 5.06% from the last session, before settling in for the closing price of $3.36. Price fluctuations for ATYR have ranged from $1.14 to $3.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 436.18% over the last five years. Company’s average yearly earnings per share was noted 2.79% at the time writing. With a float of $81.75 million, this company’s outstanding shares have now reached $83.94 million.
The firm has a total of 59 workers. Let’s measure their productivity. In terms of profitability, gross margin is -563.83%, operating margin of -28958.72%, and the pretax margin is -27155.32%.
Atyr Pharma Inc (ATYR) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Atyr Pharma Inc is 2.61%, while institutional ownership is 63.01%. The most recent insider transaction that took place on Jul 24 ’24, was worth 101,038. In this transaction Director of this company bought 52,300 shares at a rate of $1.93, taking the stock ownership to the 413,023 shares. Before that another transaction happened on Jul 22 ’24, when Company’s Director bought 41,052 for $1.74, making the entire transaction worth $71,500. This insider now owns 354,075 shares in total.
Atyr Pharma Inc (ATYR) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.00% during the next five years compared to 43.36% growth over the previous five years of trading.
Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators
Check out the current performance indicators for Atyr Pharma Inc (ATYR). In the past quarter, the stock posted a quick ratio of 5.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1288.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.80 in one year’s time.
Technical Analysis of Atyr Pharma Inc (ATYR)
Analysing the last 5-days average volume posted by the [Atyr Pharma Inc, ATYR], we can find that recorded value of 0.72 million was better than the volume posted last year of 0.59 million. As of the previous 9 days, the stock’s Stochastic %D was 54.84%. Additionally, its Average True Range was 0.26.
During the past 100 days, Atyr Pharma Inc’s (ATYR) raw stochastic average was set at 87.83%, which indicates a significant increase from 72.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.22% in the past 14 days, which was lower than the 73.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.92, while its 200-day Moving Average is $2.07. Now, the first resistance to watch is $3.76. This is followed by the second major resistance level at $3.98. The third major resistance level sits at $4.19. If the price goes on to break the first support level at $3.33, it is likely to go to the next support level at $3.12. Now, if the price goes above the second support level, the third support stands at $2.90.
Atyr Pharma Inc (NASDAQ: ATYR) Key Stats
There are currently 83,942K shares outstanding in the company with a market cap of 296.32 million. Presently, the company’s annual sales total 350 K according to its annual income of -50,390 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -16,310 K.
